Fondaparinux Sodium

Inquiry

Cat Number

API114870030

CAS Number

114870-03-0

If you have any other questions, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

114870-03-0

EINECS

686-283-7

Storage

2-8℃

Molecular Formula

C31H43N3Na10O49S8

Molecular Weight

1728.1

Smiles

CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

Appearance

White to off-white solid

Melting Point

>209℃

General Description

Fondaparinux Sodium is a synthetic pentasaccharide anticoagulant representing the minimal sequence required for antithrombin III binding. It selectively enhances Factor Xa inactivation with high specificity.

Mechanism of Action

Fondaparinux binds to the pentasaccharide binding site of antithrombin III, inducing a conformational change that accelerates Factor Xa inactivation approximately 300-fold, thereby inhibiting thrombin generation and the coagulation cascade.

Application

Used in the prevention and treatment of thromboembolic disorders. Fondaparinux Sodium is indicated for deep vein thrombosis prophylaxis post-orthopedic surgery, acute pulmonary embolism, and acute coronary syndrome management.

Fondaparinux sodium is a synthetic sulfated pentasaccharide developed from the antithrombin binding moiety of heparin. Through the activation of antithrombin, fondaparinux selectively inhibits coagulation factor Xa, which in turn inhibits the activation of thrombin and the subsequent coagulation cascade. The drug binds with high affinity to antithrombin III and catalyzes a conformational change in the serpin's reactive loop, potentiating the natural inhibitory effect of antithrombin against factor Xa by a factor of approximately 300. This potentiation results in effective and dose-dependent inhibition of thrombin generation, whether triggered by intrinsic or extrinsic pathways. Unlike low molecular weight heparins that act on multiple targets within the coagulation cascade, fondaparinux demonstrates selective factor Xa inhibition with no direct activity against thrombin. This selectivity contributes to a favorable tolerability profile, particularly with regard to the risk of major bleeding.

Fig. 1 Mechanism of action of Fondaparinux Sodium. (Robinson D M, Wellington K. 2005) Fig. 1 Mechanism of action of Fondaparinux Sodium. (Robinson D M, Wellington K. 2005)

References

Robinson D M, Wellington K. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism. American journal of cardiovascular drugs, 2005, 5(5): 335-346.

What therapeutic advantage does Fondaparinux Sodium offer over low-molecular-weight heparins?

Fondaparinux provides highly selective Factor Xa inhibition with no risk of heparin-induced thrombocytopenia and does not require routine coagulation monitoring.

What storage conditions are required?

Store at room temperature in a tightly sealed container, protected from light and moisture.

What purity grade is available?

It is supplied as a high-purity grade suitable for R&D and pharmaceutical manufacturing.

Can packaging and order quantities be customized?

Yes, both packaging formats and order quantities can be tailored to meet specific R&D and production needs.